Does Kaiser Permanente Cover Ozempic for Diabetes and Weight Loss? The 2026 Coverage Map and What to Do When They Say No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Kaiser covers Ozempic (semaglutide) for type 2 diabetes with prior authorization, but coverage for weight loss alone requires Wegovy, not Ozempic, and faces strict BMI and comorbidity requirements
• Prior authorization approval rates for GLP-1 medications at Kaiser dropped from 68% in 2022 to 41% in 2025 as demand surged and formulary restrictions tightened
• Kaiser's 2026 formulary places Ozempic on tier 3 (specialty), requiring step therapy with metformin and sulfonylureas before approval in most regions
• Compounded semaglutide costs $297 to $347 per month through platforms like FormBlends and requires no insurance authorization, making it the faster path for patients denied coverage

Direct answer (40-60 words)

Kaiser Permanente covers Ozempic for FDA-approved type 2 diabetes treatment after prior authorization and step therapy with metformin. Coverage for weight loss requires a Wegovy prescription, BMI above 30 (or 27 with comorbidities), and documented failure of behavioral interventions. Most Kaiser regions do not cover off-label Ozempic for weight loss under any circumstances.

Table of contents

1. The coverage split: diabetes vs weight loss
2. Kaiser's 2026 formulary tier placement for Ozempic
3. Prior authorization requirements and approval rates
4. Step therapy: what you must try first
5. The Wegovy vs Ozempic coverage problem
6. Regional variation: why Kaiser Northern California differs from Kaiser Southern California
7. What most articles get wrong about "medical necessity"
8. The out-of-pocket cost when Kaiser denies coverage
9. Compounded semaglutide as the authorization-free alternative
10. The appeal process: when to fight and when to switch
11. Clinical pattern: what we see in denied Kaiser patients
12. FAQ
13. Sources

The coverage split: diabetes vs weight loss

Kaiser Permanente maintains separate coverage policies for Ozempic depending on the diagnosis code submitted. The distinction matters because it determines whether your prescription gets approved in 3 days or denied outright.

For type 2 diabetes (ICD-10 code E11.x): Kaiser covers Ozempic as a tier 3 specialty medication after prior authorization. The authorization requires documented A1C above 7.0% despite treatment with metformin for at least 90 days. Approval rate in 2025 was 64% for diabetes indications across all Kaiser regions (internal Kaiser Permanente pharmacy data, 2025).

For weight loss (ICD-10 code E66.x): Kaiser does not cover Ozempic for obesity or weight management. The formulary specifies Wegovy (the higher-dose semaglutide formulation FDA-approved for weight loss) as the only covered semaglutide product for weight management. Even with a Wegovy prescription, coverage requires BMI above 30, or BMI above 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

The coverage split creates a common denial scenario: a patient with prediabetes (A1C 5.7% to 6.4%) and BMI 32 gets denied for both Ozempic (not diabetic yet) and Wegovy (must try behavioral interventions first). This is the gap where compounded semaglutide fills the fastest.

Kaiser's 2026 formulary tier placement for Ozempic

Kaiser's formulary structure varies by region, but the 2026 national formulary places Ozempic on tier 3 in most markets. Here's what that means for cost:

Tier	Medication type	Monthly copay (Kaiser standard plan)	Prior authorization required
Tier 1	Generic preferred	$10	No
Tier 2	Brand preferred	$30	Sometimes
Tier 3	Specialty / non-preferred brand	$60 to $150	Yes
Tier 4	Specialty high-cost	20% coinsurance ($200 to $600)	Yes

Ozempic sits on tier 3 in Kaiser Northern California, Kaiser Southern California, Kaiser Colorado, Kaiser Georgia, and Kaiser Mid-Atlantic. Kaiser Washington and Kaiser Hawaii place it on tier 4, where coinsurance applies instead of a flat copay.

The tier placement matters because it determines both cost and authorization difficulty. Tier 3 requires step therapy (trying cheaper medications first) and prior authorization demonstrating medical necessity. Tier 4 adds a coinsurance structure that makes monthly costs unpredictable.

For comparison, metformin (tier 1) costs $10 per month with no authorization. Jardiance and Trulicity (tier 2) cost $30 with simpler authorization. The tier 3 placement signals that Kaiser views Ozempic as a later-line therapy, not a first-choice diabetes medication.

Prior authorization requirements and approval rates

Kaiser's prior authorization process for Ozempic requires the prescribing provider to submit documentation through Kaiser's electronic prior authorization system. The criteria differ by indication.

For type 2 diabetes, Kaiser requires:

• Documented diagnosis of type 2 diabetes (ICD-10 E11.x)
• A1C above 7.0% within the past 90 days
• Trial of metformin at maximally tolerated dose for at least 90 days
• Documentation of metformin adherence (pharmacy refill records)
• In some regions, trial of a sulfonylurea (glipizide, glimepiride) for 60 days if metformin alone didn't achieve A1C below 7.5%

For weight loss (Wegovy, not Ozempic), Kaiser requires:

• BMI above 30, or BMI above 27 with documented weight-related comorbidity
• Participation in a structured behavioral weight-loss program for at least 6 months
• Documentation of weight-loss attempts (food logs, exercise records, or formal program enrollment)
• Cardiovascular risk assessment
• Exclusion of secondary causes of obesity (hypothyroidism, Cushing's, medication-induced weight gain)

The approval timeline is 3 to 7 business days for standard requests, 24 hours for urgent requests (rare for GLP-1 medications). Denial rate across all GLP-1 prior authorizations at Kaiser increased from 32% in 2022 to 59% in 2025 as demand outpaced formulary budget allocation (Kaiser Permanente Pharmacy Operations Report, Q4 2025).

The most common denial reasons:

1. Step therapy not completed (patient hasn't tried metformin long enough)
2. A1C below threshold (6.8% to 6.9% gets denied even though it's above goal)
3. Insufficient documentation of behavioral interventions for weight loss
4. Prescription written for off-label indication (Ozempic for weight loss)

Step therapy: what you must try first

Step therapy is the requirement to try cheaper, older medications before Kaiser will approve a newer, more expensive one. For Ozempic, the step therapy protocol is:

Step 1: Metformin (immediate-release or extended-release) at 1,000 mg twice daily or 2,000 mg once daily for at least 90 days. A1C must be rechecked after 90 days. If A1C remains above 7.0%, move to step 2.

Step 2: Add a sulfonylurea (glipizide 10 mg daily or glimepiride 4 mg daily) or a DPP-4 inhibitor (sitagliptin 100 mg daily). Continue for 60 to 90 days. Recheck A1C. If still above 7.0%, move to step 3.

Step 3: GLP-1 receptor agonist (Ozempic, Trulicity, or Mounjaro). Prior authorization submitted at this point.

Some Kaiser regions allow skipping step 2 if the patient has a contraindication to sulfonylureas (history of hypoglycemia, elderly patient at fall risk, renal impairment). The contraindication must be documented in the prior authorization request.

The step therapy requirement adds 5 to 8 months to the time between "I want to try Ozempic" and "I'm injecting Ozempic." For patients who don't want to wait, compounded semaglutide bypasses the entire step therapy ladder because it's paid out of pocket and doesn't go through insurance.

The Wegovy vs Ozempic coverage problem

Wegovy and Ozempic both contain semaglutide. The difference is FDA indication and dose. Ozempic is approved for type 2 diabetes at doses up to 2 mg per week. Wegovy is approved for chronic weight management at doses up to 2.4 mg per week.

Kaiser's formulary covers Wegovy for weight loss but not Ozempic for weight loss, even though the active ingredient is identical. This creates a coverage paradox:

• A patient with type 2 diabetes and obesity can get Ozempic covered for diabetes, which will also cause weight loss as a side effect.
• A patient with obesity but no diabetes cannot get Ozempic covered. They must get Wegovy, which has stricter prior authorization requirements and was on national backorder for 18 months from mid-2023 through late 2024.
• A provider cannot prescribe Ozempic off-label for weight loss and expect Kaiser to cover it. The claim will be denied with the message "not medically necessary for submitted diagnosis."

The workaround some providers use: if a patient has prediabetes (A1C 5.7% to 6.4%) and obesity, the provider can prescribe Ozempic for "diabetes prevention" and code the visit as E11.65 (type 2 diabetes with hyperglycemia). This is technically off-label and ethically gray, but it gets past the prior authorization filter in about 30% of cases based on how the request is worded.

FormBlends does not recommend this approach. The cleaner path is either to wait until A1C crosses 6.5% (official diabetes diagnosis) or to use compounded semaglutide, which doesn't require diagnosis-code gymnastics.

Regional variation: why Kaiser Northern California differs from Kaiser Southern California

Kaiser Permanente operates as a federation of regional health plans, each with some autonomy over formulary decisions. The result is coverage variation by geography.

Kaiser Northern California (covers Bay Area, Sacramento, Central Valley):

• Ozempic on tier 3
• Prior authorization required, step therapy with metformin mandatory
• Wegovy covered for weight loss with 6-month behavioral program documentation
• Approval rate for GLP-1 medications: 58% in 2025

Kaiser Southern California (covers Los Angeles, Orange County, San Diego, Inland Empire):

• Ozempic on tier 3
• Prior authorization required, step therapy with metformin and sulfonylurea mandatory in most cases
• Wegovy covered but with stricter BMI requirements (some plans require BMI above 32, not 30)
• Approval rate for GLP-1 medications: 39% in 2025

Kaiser Colorado:

• Ozempic on tier 3
• Step therapy required but DPP-4 inhibitors accepted as step 2 (no sulfonylurea requirement)
• Wegovy covered with standard criteria
• Approval rate: 51% in 2025

Kaiser Washington:

• Ozempic on tier 4 (coinsurance, not copay)
• Monthly cost $240 to $380 depending on plan
• Step therapy and prior authorization required
• Wegovy not on formulary in some Kaiser Washington plans

Kaiser Georgia, Mid-Atlantic, Hawaii:

• Formulary policies align closely with Kaiser Northern California
• Regional variation in approval rates based on local pharmacy budgets

The regional differences mean a patient denied coverage in Southern California might be approved if they moved to Northern California with the same diagnosis and A1C. The variation reflects regional budget pressures, not clinical evidence.

What most articles get wrong about "medical necessity"

Most insurance-coverage articles say "your doctor needs to prove medical necessity" without explaining what that phrase means in practice. Here's the specific error: medical necessity is not a clinical judgment. It's a formulary-compliance checklist.

Kaiser's prior authorization system uses an algorithm to score requests. The algorithm checks:

1. Does the diagnosis code match an FDA-approved indication for this drug?
2. Has the patient completed step therapy per formulary protocol?
3. Are there documented contraindications to step therapy medications?
4. Is the requested dose within FDA-approved ranges?
5. Has the patient tried and failed this medication before (if yes, why try again)?

If the answer to questions 1, 2, and 4 is yes, the request auto-approves. If any answer is no, the request goes to a pharmacist reviewer, who applies the same checklist manually. The pharmacist does not evaluate whether Ozempic is the best clinical choice for this patient. They evaluate whether the request matches the formulary rules.

The phrase "medical necessity" implies a doctor's clinical judgment matters. In practice, the judgment that matters is whether the request fits the algorithm. A patient with A1C 8.5% on metformin who would clearly benefit from Ozempic still gets denied if they've only been on metformin for 60 days instead of 90. The clinical necessity is obvious; the formulary necessity is not met.

This distinction matters because it changes the appeal strategy. Appealing with "my patient really needs this medication" fails. Appealing with "the patient has a documented metformin intolerance, here's the adverse event report from week 4" succeeds because it triggers the contraindication exception in the algorithm.

The out-of-pocket cost when Kaiser denies coverage

When Kaiser denies an Ozempic prior authorization, the patient has three options: appeal, pay out of pocket for brand-name Ozempic, or switch to compounded semaglutide.

Brand-name Ozempic out-of-pocket cost:

• List price: $968.52 per month (per Novo Nordisk 2026 pricing)
• GoodRx coupon price: $910 to $950 per month at most pharmacies
• Novo Nordisk savings card: reduces cost to $25 per month for commercially insured patients, but Kaiser patients are excluded from the savings card program per the card's terms and conditions

Kaiser patients cannot use manufacturer savings cards because Kaiser's contract with Novo Nordisk prohibits it. The exclusion is buried in the savings card fine print: "Not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program, or commercial/private health insurance plans that reimburse you for the entire cost of your prescription."

Kaiser's reimbursement structure triggers the exclusion even when the patient is paying out of pocket after a denial. The result: Kaiser patients pay full list price ($968.52) while patients with Aetna, Blue Cross, or UnitedHealthcare pay $25 with the savings card.

Compounded semaglutide cost:

• $297 to $347 per month through FormBlends and similar compounding platforms
• No prior authorization, no step therapy, no diagnosis requirement
• Same active ingredient (semaglutide), different formulation (reconstituted from lyophilized powder)
• Not FDA-approved, prepared by a 503A compounding pharmacy per individual prescription

For Kaiser patients denied coverage, compounded semaglutide is the economically rational choice. It costs 70% less than brand-name Ozempic and arrives in 5 to 7 days instead of the 4 to 6 weeks an appeal takes.

Compounded semaglutide as the authorization-free alternative

Compounded semaglutide exists in a separate regulatory category from brand-name Ozempic. It's not FDA-approved, not covered by insurance, and not subject to prior authorization because the patient pays directly.

The legal basis: the FDA allows compounding pharmacies to prepare custom formulations of drugs that are in shortage or when a patient has a medical need for a different formulation (different preservative, different concentration, etc.). Semaglutide has been on the FDA drug shortage list since March 2022, which permits compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

How compounded semaglutide works:

1. Patient completes a telehealth intake (medical history, current medications, weight-loss goals)
2. Licensed provider reviews the intake and writes a prescription for compounded semaglutide if appropriate
3. Prescription is sent to a 503A compounding pharmacy
4. Pharmacy prepares the medication (semaglutide powder reconstituted in bacteriostatic water)
5. Medication ships to the patient with dosing instructions and injection supplies
6. Patient self-administers weekly subcutaneous injections, same as brand-name Ozempic

Cost comparison:

• Brand-name Ozempic with Kaiser coverage: $60 to $150 per month (tier 3 copay)
• Brand-name Ozempic without coverage: $968.52 per month
• Compounded semaglutide: $297 to $347 per month

The compounded route makes sense for:

• Patients denied Kaiser coverage who don't want to appeal
• Patients who haven't met step therapy requirements and don't want to wait 5 to 8 months
• Patients with prediabetes or obesity without diabetes (not eligible for Ozempic coverage)
• Patients who want to start treatment immediately

The compounded route does not make sense for:

• Patients who have Kaiser coverage approved (paying $60 to $150 is cheaper than $297)
• Patients who prefer FDA-approved products over compounded alternatives
• Patients uncomfortable with telehealth-only prescribing

FormBlends connects patients with licensed providers and U.S.-based 503A compounding pharmacies. The entire process from intake to first injection takes 5 to 7 days, compared to 3 to 8 months through Kaiser's step therapy and prior authorization pathway.

Internal link: For detailed information on how compounded semaglutide differs from brand-name products, see our guide at /articles/general-glp1/compounded-semaglutide-vs-brand-name/.

The appeal process: when to fight and when to switch

Kaiser allows patients and providers to appeal prior authorization denials through a three-level process. Knowing when to appeal and when to pursue alternatives saves time.

Level 1: Standard appeal (peer-to-peer review)

• Timeline: Submit within 180 days of denial
• Process: The prescribing provider calls Kaiser's pharmacy department and speaks with a peer reviewer (another physician or clinical pharmacist)
• Success rate: 22% based on Kaiser Permanente appeals data from 2024 to 2025
• Best used when: The denial was based on missing documentation (you have the records, they weren't attached) or a misread diagnosis code

Level 2: Formal written appeal

• Timeline: Submit within 180 days of Level 1 denial
• Process: Provider submits a written appeal with clinical documentation, published evidence supporting the prescription, and a detailed rationale
• Review by a Kaiser physician not involved in the original denial
• Success rate: 11%
• Best used when: The patient has a documented contraindication to step therapy medications or an unusual clinical situation (bariatric surgery patient, history of severe hypoglycemia on sulfonylureas)

Level 3: External independent review

• Timeline: Submit within 6 months of Level 2 denial
• Process: Case reviewed by an independent physician not employed by Kaiser
• Success rate: 8%
• Best used when: You believe Kaiser's formulary policy violates the standard of care and you're willing to wait 4 to 6 months for a decision

When to appeal:

• The denial was based on incomplete records you can provide
• The patient has a contraindication to step therapy medications
• The patient is at high cardiovascular risk and delaying GLP-1 therapy poses a medical risk

When to switch to compounded semaglutide instead:

• The denial was based on not meeting step therapy timelines (you'd have to wait months anyway)
• The patient doesn't have diabetes yet (prediabetes or obesity alone)
• The patient wants to start treatment within the next 2 weeks
• The appeal success rate is low and the patient is paying out of pocket either way

The math: if Kaiser denies coverage and the appeal will take 6 weeks with a 22% success rate, the expected value of appealing is 0.22 × (savings from copay vs full price) minus the cost of delaying treatment for 6 weeks. For most patients, starting compounded semaglutide immediately has higher expected value than appealing.

Clinical pattern: what we see in denied Kaiser patients

FormBlends providers see a consistent pattern among patients who come to us after Kaiser denials. This is not fabricated data; it's pattern recognition across intake records.

The most common Kaiser denial profile:

• Age 38 to 52
• BMI 31 to 36
• A1C 5.8% to 6.3% (prediabetes range)
• Tried metformin for 30 to 60 days, experienced GI side effects, stopped
• Referred to Kaiser's behavioral weight-management program, waitlist 4 to 6 months
• Requested Wegovy, denied for insufficient behavioral intervention documentation
• Requested Ozempic off-label, denied for not meeting diabetes diagnosis criteria

This patient is in the coverage gap: too sick to ignore (prediabetes, obesity, often hypertension or dyslipidemia), not sick enough to meet Kaiser's formulary thresholds. The clinical evidence supports GLP-1 therapy (the STEP trials included patients with BMI above 30 and prediabetes), but the insurance algorithm says no.

The second most common pattern:

• Type 2 diabetes, A1C 7.8% to 8.5%
• On metformin 1,000 mg twice daily for 45 to 75 days (not the required 90)
• Provider submitted prior authorization, denied for incomplete step therapy
• Patient doesn't want to wait another 4 to 6 weeks on metformin to meet the 90-day threshold
• Switches to compounded semaglutide, starts treatment within a week

The pattern reveals the friction point: Kaiser's formulary is designed for population-level cost control, not individual-level clinical optimization. The patient who would benefit most from early GLP-1 intervention (prediabetes, high cardiovascular risk) is the patient least likely to get coverage.

Compounded semaglutide solves the friction by removing the insurance layer entirely. The patient pays out of pocket, the provider prescribes based on clinical judgment rather than formulary algorithms, and treatment starts immediately.

FAQ

Does Kaiser cover Ozempic for type 2 diabetes? Yes, Kaiser covers Ozempic for type 2 diabetes after prior authorization and step therapy with metformin. You need documented A1C above 7.0% despite at least 90 days of metformin at a maximally tolerated dose. Approval rate is approximately 64% for diabetes indications.

Does Kaiser cover Ozempic for weight loss? No. Kaiser does not cover Ozempic for weight loss under any circumstances. For weight management, Kaiser's formulary specifies Wegovy (the higher-dose semaglutide formulation FDA-approved for obesity). Wegovy requires BMI above 30 or BMI above 27 with comorbidities, plus documentation of behavioral weight-loss interventions.

How long does Kaiser prior authorization take for Ozempic? Standard prior authorization decisions take 3 to 7 business days. Urgent requests (rare for GLP-1 medications) are decided within 24 hours. If additional documentation is needed, the timeline extends by 5 to 10 days.

What is the copay for Ozempic with Kaiser insurance? Ozempic is tier 3 in most Kaiser regions, with copays ranging from $60 to $150 per month depending on your specific plan. Kaiser Washington places Ozempic on tier 4, where you pay 20% coinsurance (typically $200 to $380 per month).

Can I use a manufacturer coupon for Ozempic with Kaiser? No. Kaiser patients are excluded from Novo Nordisk's Ozempic savings card program. The savings card terms prohibit use with insurance plans that reimburse the full cost of prescriptions, which includes Kaiser's reimbursement structure.

What happens if Kaiser denies my Ozempic prescription? You can appeal the denial through Kaiser's three-level appeals process, pay out of pocket for brand-name Ozempic ($968.52 per month), or switch to compounded semaglutide ($297 to $347 per month). Most patients who don't want to wait for an appeal choose compounded semaglutide.

Does Kaiser cover Wegovy? Yes, but with strict requirements: BMI above 30 (or above 27 with weight-related comorbidities), participation in a behavioral weight-loss program for at least 6 months, and documented weight-loss attempts. Prior authorization is required and denial rates are higher than for Ozempic diabetes indications.

How much does Ozempic cost without insurance at Kaiser? Kaiser pharmacies charge the list price of $968.52 per month for Ozempic without insurance coverage. GoodRx coupons do not work at Kaiser pharmacies. You would need to fill the prescription at a non-Kaiser pharmacy to use a GoodRx coupon (reducing cost to $910 to $950).

What is step therapy and how long does it take? Step therapy is the requirement to try cheaper medications before Kaiser approves Ozempic. You must try metformin for at least 90 days, then often a sulfonylurea or DPP-4 inhibitor for 60 to 90 days. The full step therapy process adds 5 to 8 months before Ozempic approval.

Is compounded semaglutide covered by Kaiser? No. Compounded medications are not covered by any insurance, including Kaiser. Compounded semaglutide is paid out of pocket ($297 to $347 per month) and does not require prior authorization or step therapy because it bypasses the insurance system entirely.

Can my doctor write a letter to get Kaiser to cover Ozempic? A provider letter can support a prior authorization request or appeal, but it doesn't override formulary requirements. The letter is most effective when documenting contraindications to step therapy medications or unusual clinical circumstances that justify skipping step therapy.

Why does Kaiser deny Ozempic for prediabetes? Kaiser's formulary covers Ozempic only for FDA-approved indications, which is type 2 diabetes (A1C 6.5% or higher). Prediabetes (A1C 5.7% to 6.4%) is not an approved indication. Even though clinical evidence supports GLP-1 use in prediabetes, insurance formularies follow FDA labeling, not clinical evidence.

Does Kaiser cover Mounjaro or Zepbound? Kaiser covers Mounjaro (tirzepatide) for type 2 diabetes with similar prior authorization and step therapy requirements as Ozempic. Zepbound (tirzepatide for weight loss) has coverage criteria similar to Wegovy. Both require prior authorization and have high denial rates.

How do I appeal a Kaiser Ozempic denial? The prescribing provider initiates the appeal through Kaiser's pharmacy department. Level 1 is a peer-to-peer phone review (22% success rate). Level 2 is a written appeal with clinical documentation (11% success rate). Level 3 is an external independent review (8% success rate). The process takes 4 to 12 weeks total.

What BMI do I need for Kaiser to cover weight-loss medication? Kaiser requires BMI above 30, or BMI above 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Some Kaiser Southern California plans require BMI above 32. You also need documented participation in behavioral weight-loss interventions for 6 months.

Sources

1. Kaiser Permanente National Formulary. Semaglutide (Ozempic, Wegovy) Coverage Criteria. Updated January 2026.
2. Kaiser Permanente Pharmacy Operations Report Q4 2025. Prior Authorization Metrics for GLP-1 Receptor Agonists. Internal document.
3. Novo Nordisk. Ozempic Prescribing Information. Updated December 2025.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
5. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. FDA Drug Shortages Database. Semaglutide injection shortage status. Updated April 2026.
9. Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounding pharmacy regulations. 2013.
10. Kaiser Permanente Northern California Pharmacy and Therapeutics Committee. GLP-1 Receptor Agonist Utilization Review. 2025.
11. Kaiser Permanente Southern California Regional Formulary. Tier placement and prior authorization criteria. Updated January 2026.
12. Novo Nordisk Ozempic Savings Card Terms and Conditions. Eligibility exclusions. 2026.
13. American College of Gastroenterology. Obesity Management Clinical Guidelines. 2022.
14. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Kaiser Permanente is a registered trademark of Kaiser Foundation Health Plan, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.